Background: DFNB16, the second most common genetic cause of hearing loss, is caused by mutations of the STRC gene encoding stereocilin, a protein essential for the effective functioning of outer hair cells (OHCs) as cochlear amplifiers. Strc−/− mice, which lack stereocilin, display severe to profound deafness and constitute a relevant preclinical model for DFNB16.
Methods: Using Strc−/− mice, we developed a gene therapy strategy based on the use of dual AAV9-PHP.eB vectors to deliver the full-length Strc cDNA. Therapeutic efficacy was assessed by evaluating stereocilin expression, OHC bundle architecture, and their attachment to the tectorial membrane, together with functional recovery using distortion product otoacoustic emissions (DPOAEs), auditory brainstem responses (ABR) measurements and Go/No-Go behavioral testing with psychometric analysis.
Results: Dual-AAV–mediated Strc gene delivery restored stereocilin expression, OHC bundle architecture and their attachment to the tectorial membrane, leading to the recovery of cochlear amplification and hearing to near normal thresholds, as confirmed by distortion product otoacoustic emission (DPOAE) and auditory brainstem response measurements. Behavioural assessment showed that treated Strc−/− mice regained normal frequency discrimination, indicating a restoration of higher-order auditory processing, up to 100 days post-treatment.
Conclusion: These findings provide the first proof-of-principle that peripheral gene therapy can restore OHC function, cochlear amplification and central auditory perception in a DFNB16 model.
| [1] |
Petit C, Bonnet C, Safieddine S. Deafness: from genetic architecture to gene therapy. Nat Rev Genet. 2023; 24: 665-686.
|
| [2] |
Hereditary Hearing Loss Homepage. Accessed 9 October 2025 https://hereditaryhearingloss.org/
|
| [3] |
Deafness Variation Database. Accessed 6 October 2025 https://deafnessvariationdatabase.org/new
|
| [4] |
Benoit C, Carlson RJ, King M-C, et al. Behavioral characterization of the cochlear amplifier lesion due to loss of function of stereocilin (STRC) in human subjects. Hearing Res. 2023; 439:108898.
|
| [5] |
do Nascimento LT, Bevilacqua MC. Evaluation of speech perception in noise in cochlear implanted adults. Braz J Otorhinolaryngol. 2005; 71: 432-438.
|
| [6] |
Verschuure J, van Benthem PP. Effect of hearing aids on speech perception in noisy situations. Audiology. 1992; 31: 205-221.
|
| [7] |
Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet. 2020; 396: 413-446.
|
| [8] |
Wang X, Zhang L, Chen S, et al. Viral-mediated connexin 26 expression combined with dexamethasone rescues hearing in a conditional Gjb2 null mice model. Adv Sci (Weinh). 2024; 12:2406510.
|
| [9] |
Sun Q, Tan F, Zhang L, et al. Combined AAV-mediated specific Gjb2 expression restores hearing in DFNB1 mouse models. Mol Ther. 2025; 33: 3006-3021.
|
| [10] |
Akil O, Dyka F, Calvet C, et al. Dual AAV-mediated gene therapy restores hearing in a DFNB9 mouse model. Proc Natl Acad Sci USA. 2019; 116: 4496-4501.
|
| [11] |
Qi J, Tan F, Zhang L, et al. AAV-mediated gene therapy restores hearing in patients with DFNB9 deafness. Adv Sci (Weinh). 2024; 11:e2306788.
|
| [12] |
Al-Moyed H, Cepeda AP, Jung S, et al. A dual-AAV approach restores fast exocytosis and partially rescues auditory function in deaf otoferlin knock-out mice. EMBO Mol Med. 2019; 11:e9396.
|
| [13] |
Lv J, Wang H, Cheng X, et al. AAV1-hOTOF gene therapy for autosomal recessive deafness 9: a single-arm trial. The Lancet. 2024; 0.
|
| [14] |
Qi J, Zhang L, Lu L, et al. AAV gene therapy for autosomal recessive deafness 9: a single-arm trial. Nat Med. 2025; 31: 2917-2926.
|
| [15] |
Wang H, Chen Y, Lv J, et al. Bilateral gene therapy in children with autosomal recessive deafness 9: single-arm trial results. Nat Med. 2024; 30: 1898-1904.
|
| [16] |
Verpy E, Masmoudi S, Zwaenepoel I, et al. Mutations in a new gene encoding a protein of the hair bundle cause non-syndromic deafness at the DFNB16 locus. Nat Genet. 2001; 29: 345-349.
|
| [17] |
Vona B, Hofrichter MaH, Neuner C, et al. DFNB16 is a frequent cause of congenital hearing impairment: implementation of STRC mutation analysis in routine diagnostics. Clin Genet. 2015; 87: 49-55.
|
| [18] |
Francey LJ, Conlin LK, Kadesch HE, et al. Genome-wide SNP genotyping identifies the Stereocilin (STRC) gene as a major contributor to pediatric bilateral sensorineural hearing impairment. Am J Med Genet A. 2012; 158A: 298-308.
|
| [19] |
Han S, Zhang D, Guo Y, et al. Prevalence and characteristics of STRC gene mutations (DFNB16): a systematic review and meta-analysis. Front Genet. 2021; 12:707845.
|
| [20] |
Simi A, Perry J, Schindler E, et al. Audiologic phenotype and progression in pediatric STRC-related autosomal recessive hearing loss. Laryngoscope. 2021; 131: E2897-E2903.
|
| [21] |
Markova TG, Alekseeva NN, Mironovich OL, et al. Clinical features of hearing loss caused by STRC gene deletions/mutations in Russian population. Int J Pediatr Otorhinolaryngol. 2020; 138:110247.
|
| [22] |
Shubina-Oleinik O, Nist-Lund C, French C, et al. Dual-vector gene therapy restores cochlear amplification and auditory sensitivity in a mouse model of DFNB16 hearing loss. Sci Adv. 2021; 7:eabi7629.
|
| [23] |
Lesica NA. Why do hearing aids fail to restore normal auditory perception? Trends in Neurosci. 2018; 41: 174-185.
|
| [24] |
Verpy E, Weil D, Leibovici M, et al. Stereocilin-deficient mice reveal the origin of cochlear waveform distortions. Nature. 2008; 456: 255-258.
|
| [25] |
Verpy E, Leibovici M, Michalski N, et al. Stereocilin connects outer-hair-cell stereocilia to one another and to the tectorial membrane. J Comp Neurol. 2011; 519: 194-210.
|
| [26] |
Postal O, Bakay W, Dupont T, et al. Characterizing subcutaneous cortical auditory evoked potentials in mice. Hear Res. 2022; 422:108566.
|
| [27] |
Kim DO. Cochlear mechanics: implications of electrophysiological and acoustical observations. Hear Res. 1980; 2: 297-317.
|
| [28] |
Bathellier B, Ushakova L, Rumpel S. Discrete neocortical dynamics predict behavioral categorization of sounds. Neuron. 2012; 76: 435-449.
|
| [29] |
Carcea I, Insanally MN, Froemke RC. Dynamics of auditory cortical activity during behavioural engagement and auditory perception. Nat Commun. 2017; 8:14412.
|
| [30] |
Ceballo S, Piwkowska Z, Bourg J, et al. Targeted cortical manipulation of auditory perception. Neuron. 2019; 104: 1168-1179.
|
| [31] |
Maor I, Shwartz-Ziv R, Feigin L, et al. Neural correlates of learning pure tones or natural sounds in the auditory cortex. Front Neural Circuits. 2019; 13: 82.
|
| [32] |
Iranfar S, Cornille M, Roldan MS, et al. Cell tropism of adeno-associated viruses within the mouse inner ear in vivo: from embryonic to adult stages. Sci Rep. 2025; 15:13479.
|
| [33] |
Mendia C, Peineau T, Zamani M, et al. Clarin-2 gene supplementation durably preserves hearing in a model of progressive hearing loss. Mol Ther. 2024.
|
| [34] |
Bramhall NF. Use of the auditory brainstem response for assessment of cochlear synaptopathy in humans. J Acoust Soc Am. 2021; 150: 4440.
|
| [35] |
Moore DR. Listening difficulties in children: bottom-up and top-down contributions. J Commun Disord. 2012; 45: 411-418.
|
| [36] |
Emptoz A, Michel V, Lelli A, et al. Local gene therapy durably restores vestibular function in a mouse model of Usher syndrome type 1G. Proc Natl Acad Sci USA. 2017; 114: 9695-9700.
|
| [37] |
Delmaghani S, Defourny J, Aghaie A, et al. Hypervulnerability to sound exposure through impaired adaptive proliferation of peroxisomes. Cell. 2015; 163: 894-906.
|
| [38] |
McCormack A, Fortnum H. Why do people fitted with hearing aids not wear them? Int J Audiol. 2013; 52: 360-368.
|
| [39] |
Moore BCJ. Perceptual consequences of cochlear hearing loss and their implications for the design of hearing aids. Ear and Hearing. 1996; 17: 133.
|
| [40] |
Verdier A, Dominique N, Groussard D, et al. Enhanced perceptual task performance without deprivation in mice using medial forebrain bundle stimulation. Cell Rep Methods. 2022; 2:100355.
|
RIGHTS & PERMISSIONS
2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
PDF
